Ligand Pharmaceuticals
LGND
293.26
-3.68
-1.24%
Ligand Pharmaceuticals
US · LGND
#1920 by market cap
Listed 1970
293.26
-3.68
-1.24%
Live - 5344 symbols - heartbeat 221s ago
· 2026-10-08 07:58
Pre-market
293.26
0.00%
After-hours
293.26
0.00%
- Market cap
- 5.85B
- P/E (TTM)i
- 30.20
- P/Bi
- 6.04
- EPSi
- 6.13
- Div yieldi
- 0.00%
- 52W posi
- 78%
Reader sentiment
Are you bullish or bearish on LGND?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 115.80% -0.16pp
- Institutions
- 477 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund108.00%
Public Company3.26%
Individual/Insider2.23%
Government Pension Fund1.74%
Hedge Fund1.38%
Private Company0.93%
Family Office/Trust0.28%
Insurance Company0.16%
Top holders as of 2026-06-30
BlackRock
15.56% · 3.10M sh
Vanguard Portfolio Management, LLC
5.71% · 1.14M sh
Janus Henderson Group plc
5.22% · 1.04M sh
Vanguard Capital Management, LLC
5.09% · 1.01M sh
Invesco Ltd.
4.66% · 928.08K sh
State Street Global Advisors
4.15% · 826.54K sh
FMR
3.82% · 761.05K sh
Congress Asset Management Company, LLP
3.31% · 659.91K sh
Franklin Resources
2.98% · 593.09K sh
Geode Capital Management, LLC
2.95% · 589.02K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 18 buys · 32 sells
| Name | Role | Stake |
|---|---|---|
| Todd Davis | Chief Executive Officer | 0.82% |
| Jason Aryeh | Independent Director | 0.51% |
| John Kozarich | Independent Chairperson | 0.21% |
| Andrew Reardon | Chief Legal Officer | 0.18% |
| Stephen Sabba | Independent Director | 0.16% |
| Octavio Espinoza | Chief Financial Officer | 0.14% |
| John LaMattina | Independent Director | 0.13% |
| Nancy Gray | Independent Director | 0.04% |
| Jason Haas | Independent Director | 0.02% |
| Martine Zimmermann | Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-21 | Martine Zimmermann | Director | Sale to Issuer | -115 | $298.50 |
| 2026-09-09 | Martine Zimmermann | Director | Open Market Disposition | -1,200 | $285.00 |
| 2026-09-02 | Andrew Reardon | Chief Legal Officer | Automatic Disposition | -5,000 | $283.99–288.98 |
| 2026-08-11 | Jason Haas | Independent Director | Open Market Disposition | -1,000 | $292.81 |
| 2026-08-11 | Jason Haas | Independent Director | Derivative Exercise and Sale | -6,138 | $51.56–292.81 |
| 2026-08-11 | Octavio Espinoza | Chief Financial Officer | Derivative Exercise and Sale | -31,641 | $52.84–292.07 |
| 2026-08-02 | Andrew Reardon | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $52.27–292.82 |
| 2026-06-30 | Andrew Reardon | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $52.27–317.15 |
| 2026-06-29 | Todd Davis | Chief Executive Officer | Other Acquisition | +132 | $160.71 |
| 2026-06-29 | Andrew Reardon | Chief Legal Officer | Other Acquisition | +132 | $160.71 |
| 2026-06-29 | Octavio Espinoza | Chief Financial Officer | Other Acquisition | +17 | $160.71 |
| 2026-06-15 | Stephen Sabba | Independent Director | Derivative Exercise and Sale | -2,145 | $66.13–254.00 |
| 2026-06-11 | Jason Haas | Independent Director | Open Market Disposition | -2,461 | $256.08 |
| 2026-06-11 | Jason Haas | Independent Director | Derivative Exercise and Sale | -4,000 | $51.56–256.08 |
| 2026-06-10 | Jason Aryeh | Independent Director | Open Market Disposition | -5,000 | $250.00 |
| 2026-06-10 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -4,500 | $249.97 |
| 2026-06-09 | John LaMattina | Independent Director | Open Market Disposition | -4,591 | $247.22–251.62 |
| 2026-06-09 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -5,000 | $249.35 |
| 2026-06-09 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -500 | $249.96 |
| 2026-06-04 | John Kozarich | Independent Chairperson | Other Acquisition | +836 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:58:31 · For reference only, not investment advice and not tailored to your situation.